Exchange: NYSE
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:00 PM ET 4/5/2013
Last 10 Quotes:
What's This?
The "insider return" statistic is based on the return generated (during the period shown) by a portfolio consisting of long positions in the stock corresponding to each purchase and short positions for each sale. The "insider grade" is calculated by testing the statistical significance of the timing of the insiders' trades; a grade of A means that if the same trades were made with random timing, there would be no more than a 5% chance of exceeding the insiders' return.
| Date | Insider | Relationship | Transaction Type | Number of Shares | Price | Market Value |
|---|---|---|---|---|---|---|
| 369 found. 1 through 20 displayed. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 [Next] | ||||||
| 4/03/2013 | Scott M. Whitcup, MD | CSO & EVP-Research & Development | S | 13,195 | 115.00 | $1,517,425 |
| 4/03/2013 | Scott M. Whitcup, MD | CSO & EVP-Research & Development | M | 13,195 | 36.15 | $476,999 |
| 4/01/2013 | Scott M. Whitcup, MD | CSO & EVP-Research & Development | S | 8,000 | 111.70 | $893,600 |
| 4/01/2013 | Scott M. Whitcup, MD | CSO & EVP-Research & Development | M | 8,000 | 41.24 | $329,920 |
| 3/26/2013 | Scott M. Whitcup, MD | CSO & EVP-Research & Development | S | 11,484 | 112.00 | $1,286,208 |
| 3/26/2013 | Scott M. Whitcup, MD | CSO & EVP-Research & Development | M | 11,484 | 36.15 | $415,147 |
| 3/21/2013 | Scott M. Whitcup, MD | CSO & EVP-Research & Development | S | 4,925 | 112.00 | $551,600 |
| 3/21/2013 | Scott M. Whitcup, MD | CSO & EVP-Research & Development | M | 4,925 | 36.15 | $178,039 |
| 3/21/2013 | Scott M. Whitcup, MD | CSO & EVP-Research & Development | S | 1,191 | 112.00 | $133,392 |
| 3/21/2013 | Scott M. Whitcup, MD | CSO & EVP-Research & Development | M | 1,191 | 36.15 | $43,055 |
| 3/15/2013 | Trevor Mervyn Jones, PhD | Director | S | 2,000 | 108.68 | $217,360 |
| 3/15/2013 | Trevor Mervyn Jones, PhD | Director | M | 1,000 | 60.60 | $60,600 |
| 3/05/2013 | Stephen J. Ryan, MD | Director | S | 5,700 | 110.00 | $627,000 |
| 3/05/2013 | Stephen J. Ryan, MD | Director | M | 5,700 | 60.60 | $345,420 |
| 2/28/2013 | Julian S. Gangolli | Corporate Vice President | G | 4,301 | 0.00 | $0 |
| 2/28/2013 | Julian S. Gangolli | Corporate Vice President | G | 4,301 | 0.00 | $0 |
| 2/20/2013 | Julian S. Gangolli | Corporate Vice President | F | 2,699 | 108.08 | $291,708 |
| 2/20/2013 | Scott M. Whitcup, MD | CSO & EVP-Research & Development | F | 5,218 | 108.08 | $563,961 |
| 2/20/2013 | David J. Endicott, MBA | President | F | 2,794 | 108.08 | $301,976 |
| 2/20/2013 | James F. Barlow | Senior Vice President & Controller | F | 1,278 | 108.08 | $138,126 |
